MJMelissa R. Junttila

Melissa R. Junttila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa R. Junttila has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma

    by Pietri Puustinen, Melissa R. Junttila, Sari Vanhatupa, Anna A. Sablina, Melissa E. Hector, Kaisa Teittinen, Olayinka Raheem, Kirsi Ketola, Shujun Lin, Juergen Kast, et al.

    Extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway activity is regulated by the antagonist function of activating kinases and inactivating protein phosphatases. Sustained ERK pathway activity is commonly observed in human malignancies; however, the mechanisms by which the pathway is protected from phosphatase-mediated inactivation in the tumor tissue remain obscure. Here, we show that methylesterase PME-1–mediated inhibition of the protein phosphatase 2A promotes basal ERK pathway activity and is required for efficient growth factor response. Mechanistically, PME-1 is shown to support ERK pathway signaling upstream of Raf, but downstream of growth factor receptors and protein kinase C. In malignant gliomas, PME-1 expression levels correlate with both ERK activity and cell proliferation in vivo. Moreover, PME-1 expression significantly correlates with disease progression in human astrocytic gliomas (n = 222). Together, these observations identify PME-1 expression as one mechanism by which ERK pathway activity is maintained in cancer cells and suggest an important functional role for PME-1 in the disease progression of human astrocytic gliomas. [Cancer Res 2009;69(7):2870–7]


  • Mechanisms of MYC stabilization in human malignancies

    by Melissa R. Junttila, Jukka Westermarck

    MYC is a pleiotropic transcription factor that has been linked to a diverse range of cellular functions, such as cell cycle regulation, proliferation, growth, differentiation and metabolism. Not surprisingly, aberrant MYC signaling has been observed in human cancers and MYC has been demonstrated to promote cell transformation and tumor progression. Here we discuss recent discoveries that have expanded our knowledge of MYC protein stability. In particular we focus on mechanisms that might explain the increased stability of MYC often observed in human cancers and cell lines. We also summarize our recent characterization of Cancerous inhibitor of PP2A (CIP2A(/KIAA1524)) as a protein that inhibits PP2A-mediated MYC dephosphorylation and proteolytic degradation. Finally, we discuss the potential relevance of mechanisms that regulate MYC stability for tumor formation in the context of cancer therapy.